Pentamycin - Lumavita

Drug Profile

Pentamycin - Lumavita

Alternative Names: Antibiotic A-246; Cogomycin; FemiFect; Fungichromin; Lagosin; LMV-602; N-Pent; NP 401; NP 402; NP 403; NP 404; Pruri-Ex; SPK-0602

Latest Information Update: 11 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Necura Pharmaceuticals AG
  • Developer Lumavita; Necura Pharmaceuticals AG
  • Class Anti-infectives; Macrolides; Polyenes; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Vaginitis
  • Discontinued Cancer; Candidiasis; Intestinal infections; Skin and soft tissue infections

Most Recent Events

  • 11 Mar 2015 Discontinued - Preclinical for Vaginitis (LMV 602) in Switzerland (Vaginal)
  • 11 Mar 2015 No recent reports on development identified - Preregistration for Vaginitis in Asia, Commonwealth of Independent States, Latin America and North Africa (Vaginal)
  • 11 Mar 2015 No recent reports on development identified - Registered for Vaginitis in Switzerland (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top